drugset / Trial / NCT06215144
Study to Evaluate NRCT-101SR in Pediatric Subjects With ADHD
RandomizedParallel-groupQuadruple-blindTreatment
Summary
To evaluate the efficacy and safety of NRCT-101SR compared to placebo in subjects 13-17 years of age with ADHD
Timeline
- Start
- 2024-01-25
- Primary completion
- 2025-10-10
- Completion
- 2025-11-06
Outcome
Outcome not reported
Stopped (Enrollment): “Slow enrollment”
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | NRCT-101SR | Unknown | 2000 mg | — |
| Subject | NRCT-101SR | Unknown | 2250 mg | — |